KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Finished Goods for 8 consecutive years, with $32.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods rose 22.34% year-over-year to $32.3 million, compared with a TTM value of $32.3 million through Dec 2025, up 22.34%, and an annual FY2025 reading of $32.3 million, up 22.34% over the prior year.
  • Finished Goods was $32.3 million for Q4 2025 at Alnylam Pharmaceuticals, down from $38.8 million in the prior quarter.
  • Across five years, Finished Goods topped out at $38.8 million in Q3 2025 and bottomed at $7.0 million in Q4 2021.
  • Average Finished Goods over 5 years is $23.6 million, with a median of $25.4 million recorded in 2022.
  • The sharpest move saw Finished Goods crashed 44.81% in 2021, then surged 265.54% in 2022.
  • Year by year, Finished Goods stood at $7.0 million in 2021, then soared by 265.54% to $25.6 million in 2022, then dropped by 1.89% to $25.1 million in 2023, then increased by 5.21% to $26.4 million in 2024, then increased by 22.34% to $32.3 million in 2025.
  • Business Quant data shows Finished Goods for ALNY at $32.3 million in Q4 2025, $38.8 million in Q3 2025, and $33.7 million in Q2 2025.